• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Intraday Session

    5/31/24 12:31:09 PM ET
    $ANEB
    $ANVS
    $CCM
    $CLDI
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANEB alert in real time by email

    Gainers

    • Novo Integrated Sciences (NASDAQ:NVOS) shares rose 120.0% to $0.99 during Friday's regular session. The company's market cap stands at $18.9 million.
    • Anebulo Pharmaceuticals (NASDAQ:ANEB) shares increased by 33.33% to $2.8. The company's market cap stands at $72.6 million.
    • Annovis Bio (NYSE:ANVS) stock increased by 21.33% to $7.28. The market value of their outstanding shares is at $81.3 million.
    • Vaccinex (NASDAQ:VCNX) stock increased by 20.96% to $6.29. The market value of their outstanding shares is at $9.9 million.
    • Genprex (NASDAQ:GNPX) stock moved upwards by 19.42% to $2.89. The company's market cap stands at $6.0 million.
    • Purple Biotech (NASDAQ:PPBT) shares moved upwards by 19.35% to $1.02. The market value of their outstanding shares is at $26.6 million.

    Losers

    • Calidi Biotherapeutics (AMEX:CLDI) stock declined by 31.0% to $0.21 during Friday's regular session. The company's market cap stands at $10.5 million.
    • Summit Therapeutics (NASDAQ:SMMT) shares decreased by 19.13% to $8.83. The company's market cap stands at $6.1 billion.
    • Heart Test Laboratories (NASDAQ:HSCS) shares fell 17.63% to $5.61. The market value of their outstanding shares is at $3.6 million.
    • Humacyte (NASDAQ:HUMA) shares fell 17.48% to $7.51. The market value of their outstanding shares is at $894.2 million.
    • Concord Medical Services (NYSE:CCM) stock decreased by 17.12% to $0.5. The market value of their outstanding shares is at $21.7 million.
    • Pulse Biosciences (NASDAQ:PLSE) shares declined by 16.1% to $10.11. The market value of their outstanding shares is at $558.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ANEB alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANEB
    $ANVS
    $CCM
    $CLDI

    CompanyDatePrice TargetRatingAnalyst
    Pulse Biosciences Inc
    $PLSE
    1/30/2026$25.00Outperform
    Mizuho
    Summit Therapeutics Inc.
    $SMMT
    12/17/2025$18.00Underweight → Equal Weight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    11/18/2025Peer Perform
    Wolfe Research
    Summit Therapeutics Inc.
    $SMMT
    9/17/2025$13.00Underweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    9/4/2025$40.00Buy
    Guggenheim
    Humacyte Inc.
    $HUMA
    8/27/2025$3.50Overweight
    Barclays
    Summit Therapeutics Inc.
    $SMMT
    8/19/2025$21.00Neutral
    Piper Sandler
    Pulse Biosciences Inc
    $PLSE
    7/7/2025$22.00Outperform
    Oppenheimer
    More analyst ratings

    $ANEB
    $ANVS
    $CCM
    $CLDI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffman Michael B bought $193,794 worth of shares (45,000 units at $4.31), increasing direct ownership by 2% to 2,574,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    12/8/25 8:05:14 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,529,739 units (SEC Form 4)

    4/A - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 6:59:54 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Hoffman Michael B bought $159,886 worth of shares (39,200 units at $4.08), increasing direct ownership by 2% to 2,519,739 units (SEC Form 4)

    4 - Annovis Bio, Inc. (0001477845) (Issuer)

    11/25/25 12:26:46 PM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    $ANVS
    $CCM
    $CLDI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer

    Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'sTecentriq® AUSTIN, Texas, Feb. 23, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that the Japanese Patent Office has issued a favorable Appeal Decision to grant a patent claiming the use of Reqorsa® Gene Therapy in combination with PD-L1 antibodies to treat cancer. Also, the European Patent Office has issued a Decision to Grant relating to a patent for the combination of REQORSA and PD-1 antibodies to treat cancer. Genprex

    2/23/26 8:00:00 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Incentive Plan, but under the terms of the 2017 Inducement Equity Incentive Plan. The equity awards were approved and issued on February 18, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). Pulse has awarded inducement options to two new employees to purchase, in aggregate, up to 19,000 shares of Company common stock. The Company's i

    2/20/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference

    SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approach to the use of BiTEs in solid tumors by utilizing its systemically delivered RedTail platform at the AACR Immuno-Oncology (AACR-IO) conference being held in Los Angeles, California. A link to the poster is available here and on the company's website. RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the tumor microenvironment (TME), and enable high-level expression of therapeutic genetic payloa

    2/20/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ANEB
    $ANVS
    $CCM
    $CLDI
    SEC Filings

    View All

    Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Genprex, Inc. (0001595248) (Filer)

    2/23/26 8:08:16 AM ET
    $GNPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    2/19/26 4:28:11 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form S-3 filed by Pulse Biosciences Inc

    S-3 - PULSE BIOSCIENCES, INC. (0001625101) (Filer)

    2/19/26 4:22:58 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ANEB
    $ANVS
    $CCM
    $CLDI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Commercial Officer Danahy Kevin Patrick exercised 60,000 shares at a strike of $1.53 and sold $1,410,600 worth of shares (60,000 units at $23.51) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/17/26 8:47:42 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Danahy Kevin Patrick exercised 60,000 shares at a strike of $1.53 and sold $1,403,400 worth of shares (60,000 units at $23.39) (SEC Form 4)

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/11/26 7:46:34 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Sainz Maria

    4 - PULSE BIOSCIENCES, INC. (0001625101) (Issuer)

    2/6/26 9:21:10 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ANEB
    $ANVS
    $CCM
    $CLDI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Mizuho initiated coverage on Pulse Biosciences with a new price target

    Mizuho initiated coverage of Pulse Biosciences with a rating of Outperform and set a new price target of $25.00

    1/30/26 6:44:12 AM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Summit Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Summit Therapeutics from Underweight to Equal Weight and set a new price target of $18.00

    12/17/25 8:48:06 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Summit Therapeutics

    Wolfe Research initiated coverage of Summit Therapeutics with a rating of Peer Perform

    11/18/25 8:28:20 AM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    $ANVS
    $CCM
    $CLDI
    Leadership Updates

    Live Leadership Updates

    View All

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. "We are delighted to welcome Maria to our Board of Directors," said Pulse Biosciences' Co-Chairman of the Board Robert W. Duggan. "She brings an exceptionally strong track record of guiding both public and private medical device companies through growth, commercialization, viability, and scale. Her strategic and operational expertise will be invaluable as Pulse begins creating and disrupting interventional m

    1/9/26 7:00:00 AM ET
    $AVNS
    $HYPR
    $OFIX
    Industrial Specialties
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Medical/Dental Instruments

    Annovis Provides Corporate Updates and Reports Third Quarter 2025 Financial Results

    MALVERN, Pa., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and third quarter 2025 financial results. "The past quarter delivered breakthrough progress on every front," said Maria Maccecchini, Ph.D., President and CEO of Annovis. "Our pivotal Phase 3 Alzheimer's study has achieved full activation across all clinical sites, with enrollment momentum advancing every day. We have fortified our intellectual property position by transferring al

    11/12/25 8:00:00 AM ET
    $ANVS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANEB
    $ANVS
    $CCM
    $CLDI
    Financials

    Live finance-specific insights

    View All

    Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

    Pulse Biosciences, Inc. (NASDAQ:PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation Highlighted 100% procedural success, or freedom from atrial fibrillation (AF), at 6 months and 96% procedural success at one year, of evaluable patients, following treatments with the nPulse Cardiac Catheter System in the first-in-human feasibility study which was presented as late-breaking data at the 31st Annual AF Symposium Meeting. Receiv

    2/19/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

    Conference Call to be Held at 4:30pm ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an earnings call to announce its fourth quarter and full year 2025 financial results and provide an operational update for the Company on Monday, February 23, 2026, after the market closes. Summit will host a live webcast of the earnings conference call at 4:30pm ET, which will be accessible through our website, www.smmttx.com. An archived edition of the session will be available on our website. About Summit Therapeutics Summit Therapeutics Inc. is a biopharmaceutical oncology company focused on the discovery, development, and commercialization of patient-, phy

    2/17/26 5:05:00 PM ET
    $SMMT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

    Pulse Biosciences, Inc. (NASDAQ:PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested in listening to the conference call may do so by dialing 1-800-715-9871 from the U.S. or 1-646-307-1963 internationally and providing Conference ID 7647402. A live and recorded webcast of the event will be available on the Pulse Bioscie

    2/4/26 4:05:00 PM ET
    $PLSE
    Medical/Dental Instruments
    Health Care

    $ANEB
    $ANVS
    $CCM
    $CLDI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/20/24 7:10:08 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Vaccinex Inc.

    SC 13D/A - VACCINEX, INC. (0001205922) (Subject)

    11/18/24 4:15:28 PM ET
    $VCNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Humacyte Inc.

    SC 13D/A - Humacyte, Inc. (0001818382) (Subject)

    11/18/24 4:10:14 PM ET
    $HUMA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care